ImpediMed Ltd.

ImpediMed's SOZO® Digital Health Platform Aligns with Updated Survivorship Standard, Marking a Milestone in Lymphedema Management CARLSBAD, Calif., Oct. 31, 2024 /PRNewswire/ -- ImpediMed, a leader in medical technologies to clinically monitor and manage fluid and body composition, today announced the National Accreditation Program for Breast Centers (NABPC) has updated its 2024 accreditation standards and, for the first time, these standards include lymphedema prevention programs utilizing bioimpedance spectroscopy (BIS) as an evidence-based guideline for managing lymphedema. As a pioneer in the field of lymphedema detection and monitoring, ImpediMed offers the only FDA-cleared BIS technology for the clinical assessment of breast cancer-related lymphedema (BCRL) –– the SOZO® Digital Health Platform. The NAPBC is a quality program of the American College of Surgeons, and the NAPBC-accredited programs must understand, implement, and demonstrate compliance with accreditation standards outlined in Optimal Resources for Breast Care. To maintain accreditation, centers must monitor their compliance with these standards and prepare for onsite review every three years. The 2024 Standards focus on the entire patient care journey from screening and prevention, to diagnosis, treatment, and survivorship, with an emphasis on providing value-based multidisciplinary care. The updated NABPC Standard for Survivorship specifies that NABPC-accredited programs must use evidence-based guidelines to manage survivorship. Examples include, but are not limited to:1 Referral to outpatient rehabilitation for evaluation and treatment of lymphedema, as needed. Use of a lymphedema prevention program, including regular symptom assessment and clinical evaluation using objective measurements, such as bioimpedance spectroscopy. "As Breast Cancer Awareness month wraps up, it's especially noteworthy that the NABPC's accreditation standards now recognize BIS as a hallmark of top-tier lymphedema care," said Dr. Parmjot Bains, Managing Director and CEO of Impedimed. "This isn't just an acknowledgement of the impact of BIS technology—it's a beacon of hope for breast cancer survivors everywhere. By including BIS, the NABPC—whose standards are penned by leading U.S. breast cancer experts—is sending a powerful message. They're not just influencing clinicians and healthcare facilities; they're reshaping the landscape of patient care, pushing this innovative approach closer to becoming the gold standard in survivorship support." Lymphedema, a disabling swelling that is a common consequence of cancer treatment, poses significant challenges in healthcare. According to the American Cancer Society, 58% of cancer patients diagnosed with breast cancer, melanoma, or pelvic area cancers are at risk for developing limb lymphedema. For breast cancer patients specifically, this risk can escalate depending on the type of treatment received. BIS is a groundbreaking technology that is revolutionizing lymphedema care that offers a noninvasive, quick, and highly sensitive method for detecting fluid changes in the body. By sending a small electrical current through the body and measuring the resistance, BIS can identify subclinical lymphedema long before visible symptoms appear – critical for preventing the progression to chronic lymphedema, enabling timely intervention and better outcomes. ImpediMed's platform is broadly accepted and recognized for effective and accurate screening of lymphedema, with U.S. health insurers now providing coverage for over 146 million covered lives. To access the full Optimal Resources for Breast Care (2024 Standards) visit the American College of Surgeons' website. 1Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the American College of Surgeons. Content does not reflect the views or interpretations of the American College of Surgeons. About ImpediMed ImpediMed is a leading global medical technology company that designs and manufactures medical devices that employ bioimpedance spectroscopy (BIS) technology for use in the noninvasive clinical assessment and monitoring of fluid status and tissue composition in patients. The company consistently drives innovation, directing its primary efforts toward addressing the specific challenges and devastating burden of secondary lymphedema with a focus on breast cancer-related lymphedema (BCRL). With its SOZO® Digital Health Platform and L-Dex®, ImpediMed is the only company to offer an FDA-cleared technology that uses BIS and is setting new standards in early detection and management of BCRL. For more information, please visit . About SOZO Digital Health Platform SOZO, the world's most advanced, non-invasive bioimpedance spectroscopy (BIS) device, delivers a precise snapshot of fluid status and tissue composition in less than 30 seconds. Using ImpediMed's BIS technology, SOZO measures 256 unique data points over a wide spectrum of frequencies from 3 kHz to 1000 kHz. Results are available immediately online for easy data access and sharing across an entire healthcare system. The FDA-cleared, CE-marked and ARTG-listed digital health platform aids in the early detection of secondary lymphoedema, provides fluid status for patients living with heart or renal failure, and can be used to monitor and maintain overall health – all on a single device. Media Contact: Jodi Perkins Amendola Communications, on behalf of ImpediMed [email protected] SOURCE ImpediMed WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

SANTA CLARA, Calif.--( BUSINESS WIRE )-- HeartBeam, Inc . (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights wherever the patient is, announced the appointment of Timothy Cruickshank as Chief Financial Officer (CFO), effective immediately. Mr. Cruickshank brings more than 15 years of public company experience with a focus on growing businesses with disruptive technologies through authentic leadership, strategic focus, data-driven decisions, and strong risk management and governance. He succeeds long-time CFO Richard Brounstein, who has been serving in an advisory capacity since retiring in February. “Tim has an outstanding record of delivering results and creating value and will be a strong partner in ensuring we have a solid financial position as we strive to make our vision to transform the monitoring and detection of cardiac conditions a reality,” said Branislav Vajdic, PhD, Chief Executive Officer and Founder of HeartBeam. “We thank Rick for his leadership over the past 9 years as he worked tirelessly to establish the strong financial foundation for the company which will continue to serve us well moving forward.” HeartBeam has developed a cable-free, credit card-sized device that captures the heart’s electrical signals from three dimensions and is designed to be capable of synthesizing a 12-lead ECG. The Company’s first 510(k) submission for its proprietary technology is currently under review with the FDA and is the cornerstone submission upon which future submissions will be based. The Company has 13 issued US patents and 4 issued international patents supporting the underlying technology. “The ability of HeartBeam’s unique technology to unlock actionable heart intelligence from three dimensions for a range of cardiac conditions is truly compelling to me,” said Mr. Cruickshank. “I am excited to join the Company at this pivotal time and look forward to working with the team to commercialize this impactful innovation, drive financial excellence and expand our impact to ultimately improving cardiac care for patients.” Mr. Cruickshank, age 43, was a financial executive of ImpediMed since 2008 and served as CFO from October 2019 through March 2024. ImpediMed is a medical technology company that designs and manufactures medical devices and software services employing its pioneering bioimpedance spectroscopy (BIS) technology for multiple indications including heart failure, protein calorie malnutrition, and lymphedema within oncology. During Mr. Cruickshank’s time at ImpediMed, he spearheaded the evolution of the company from a traditional medical device company to a medical technology company with a high margin Software-as-a-Service (SaaS) business model, through the launch of the SOZO® Digital Health Platform. He received a Master of Business Administration from Keller Graduate School of Management and a Bachelor of Science in Accounting from Syracuse University. About HeartBeam, Inc. HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming cardiac care by providing powerful cardiac insights wherever the patient is. The Company is creating the first ever cable-free 12-lead ECG capable of capturing the heart’s electrical signals from three dimensions. This platform technology is designed to be used in portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. The Company holds 13 US and 4 international issued patents related to technology enablement. For additional information, visit HeartBeam.com . Forward-Looking Statements All statements in this release that are not based on historical fact are "forward-looking statements." While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our Forms 10-K, 10-Q and other reports filed with the SEC and available at www.sec.gov . We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

Study recommends that patients be monitored a minimum of three years after cancer treatment CARLSBAD, Calif., July 16, 2024 /PRNewswire/ -- Some breast cancer patients remain at risk for developing lymphedema well after their cancer treatment is concluded and should be monitored a minimum of three years, according to data published in the Annals of Surgical Oncology. Lymphedema, a disabling swelling that is a common consequence of cancer treatment, poses significant challenges in healthcare. According to the American Cancer Society, 58% of cancer patients diagnosed with breast cancer, melanoma, or pelvic area cancers are at risk for developing limb lymphedema. Additionally, over 80% of breast cancer patients can be at risk based on the type of cancer treatment they have received. Among the paper's co-authors are Steven Chen, MD, MBA, Chief Medical Officer of ImpediMed, a pioneer in the field of medical technology that has the only FDA-cleared bioimpedance spectroscopy (BIS) technology for the clinical assessment of breast cancer-related lymphedema (BCRL) - the SOZO® Digital Health Platform. "BCRL can develop years after cancer treatment is concluded and can progress from the subclinical stage, where intervention is possible to reverse progression, to chronic lymphedema, where this can become a lifelong condition," Chen said. "This study highlights the importance of continued monitoring for BCRL post cancer treatment for at least 3 years using the most accurate technology available for early detection." Evidence from the study, titled "Timing of Breast Cancer-related Lymphedema Development Over Three Years: Observations from a Large, Prospective Randomized Screening Trial," is drawn from PREVENT, the largest randomized control trial for lymphedema assessment. PREVENT monitored progression to BCRL following intervention for BCRL assessed by BIS versus a tape measure. The results demonstrated that early detection and intervention using BIS resulted in lower progression to chronic lymphedema compared to using a tape measure. The results provide additional evidence supporting the need for continued lymphedema follow-up and the use of BIS as the preferred method, when available, as stated in national and international clinical practice guidelines. ImpediMed's platform is broadly accepted and recognized for effective and accurate screening of lymphedema, with U.S. payors now providing coverage for over 140 million covered lives. "Late-developing chronic breast cancer-related lymphedema is a particularly harsh blow to patients who thought they had put their treatment behind them," said Chirag Shah, MD, Co-Director of the Comprehensive Breast Cancer Program, Cleveland Clinic, lead author of the study, and scientific adviser to ImpediMed. "Early detection and intervention are the keys to preventing chronic lymphedema. By showing that patients can develop breast cancer-related lymphedema from a few months to even years after treatment, this analysis highlights the need for careful screening for years following treatment." The study comes on the heels of new guidance from the Multinational Association of Supportive Care in Cancer (MASCC), which also underscored the importance of regular monitoring for BCRL using BIS. The consensus-based recommendation by MASCC, coupled with supportive findings from the PREVENT trial, underscores the effectiveness of ImpediMed's technology in preventing the progression of lymphedema. The company's commitment to innovation and patient care is further evidenced by its active role in the medical community, including its participation in upcoming U.S. conferences and contributions to ongoing clinical research. As ImpediMed continues to champion early lymphedema detection and prevention, its efforts are paving the way for a new standard in breast cancer survivorship care, ensuring that survivors can look forward to healthier, more comfortable futures. About SOZO Digital Health Platform SOZO, the world's most advanced, non-invasive bioimpedance spectroscopy (BIS) device, delivers a precise snapshot of fluid status and tissue composition in less than 30 seconds. Using ImpediMed's BIS technology, SOZO measures 256 unique data points over a wide spectrum of frequencies from 3 kHz to 1000 kHz. Results are available immediately online for easy data access and sharing across an entire healthcare system. The FDA-cleared, CE-marked and ARTG-listed digital health platform aids in the early detection of secondary lymphoedema, provides fluid status for patients living with heart or renal failure, and can be used to monitor and maintain overall health – all on a single device. About ImpediMed ImpediMed is a leading global medical technology company that designs and manufactures medical devices that employ bioimpedance spectroscopy (BIS) technology for use in the noninvasive clinical assessment and monitoring of fluid status and tissue composition in patients. The company consistently drives innovation, directing its primary efforts toward addressing the specific challenges and devastating burden of secondary lymphedema with a focus on breast cancer-related lymphedema (BCRL). With its SOZO® Digital Health Platform and L-Dex®, ImpediMed is the only company to offer an FDA-cleared technology that uses BIS and is setting new standards in early detection and management of BCRL. For more information, please visit . Media Contact: Jodi Perkins Amendola Communications, on behalf of ImpediMed [email protected] SOURCE ImpediMed